• 1
    De Hert M, Schreurs V, Sweers K et al. Typical and atypical antipsychotics differentially affect long-term incidence rates of the metabolic syndrome in first-episode patients with schizophrenia: A retrospective chart review. Schizophr Res 2008;101:295303.
  • 2
    Yumru M, Savas HA, Kurt E et al. Atypical antipsychotics related metabolic syndrome in bipolar patients. J Affect Disord 2007;98:247252.
  • 3
    Birkenaes AB, Birkeland KI, Engh JA et al. Dyslipidemia independent of body mass in antipsychotic-treated patients under real-life conditions. J Clin Psychopharmacol 2008;28:132137.
  • 4
    Guo JJ, Keck PE Jr, Corey-Lisle PK et al. Risk of diabetes mellitus associated with atypical antipsychotic use among patients with bipolar disorder: A retrospective, population-based, case-control study. J Clin Psychiatry 2006;67:10551061.
  • 5
    Brooks JO, Chang HS, Krasnykh O. Metabolic risks in older adults receiving second-generation antipsychotic medication. Curr Psychiatr Rep 2009;11:3340.
  • 6
    Cascade E, Kalali AH, Cummings JL. Use of atypical antipsychotics in the elderly. Psychiatry (Edgemont) 2008;5:2831.
  • 7
    Sicras-Mainar A, Blanca-Tomayo M, Regas-Gutierrez J et al. Metabolic syndrome in outpatients receiving antipsychotic therapy in routine clinical practice: A cross-sectional assessment of a primary health care database. Eur Psychiatry 2008;23:100108.
  • 8
    Mathys M, Balszczyk A, Busti A. Incidence of abnormal metabolic parameters and weight gain induced by atypical antipsychotics in elderly patients with dementia. Consult Pharm 2009;24:201209.
  • 9
    Albert SG, Grossberg GT, Thaipisuttikul PJ et al. Atypical antipsychotics and the risk of diabetes in an elderly population in long-term care: A retrospective nursing home chart review study. J Am Med Dir Assoc 2009;10:115119.
  • 10
    Etminan M, Streiner DL, Rochon PA. Exploring the association between atypical neuroleptic agents and diabetes mellitus in older adults. Pharmacotherapy 2003;23:14111415.
  • 11
    Barnett M, Argo T, Alexander B et al. A regional comparison of developing diabetes among VA patients exposed to typical and atypical antipsychotics relative to corticosteroids and proton pump inhibitors. Ann Clin Psychiatry 2006;18:17.
  • 12
    Zheng L, Mack WJ, Dagerman KS et al. Metabolic changes associated with second-generation antipsychotic use in Alzheimer's disease patients: The CATIE-AD Study. Am J Psychiatry 2009;166:583590.
  • 13
    Rabins PV, Blacker D, Rovner BW et al. Practice guideline for the treatment of patients with Alzheimer's disease and other dementias [on-line]. Arlington (VA): American Psychiatric Association, 2007. Available at Accessed March 5, 2010.
  • 14
    Rocha FL, Hara C, Ramos ML et al. An exploratory open-label trial of ziprasidone for the treatment of behavioral and psychological symptoms of dementia. Dement Geriatr Cogn Disord 2006;22:445448.
  • 15
    Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992;45:613619.
  • 16
    Centers for Disease Control and Prevention. Percentage of civilian, noninstitutionalized population with diagnosed diabetes, by age, United States, 1980–2007 [on-line] July 29, 2009. Available at Accessed March 9, 2010.
  • 17
    American Diabetes Association. Diabetes statistics [on-line]. Available at Accessed March 9, 2010.
  • 18
    Rockwood K, Awalt E, MacKnight C et al. Incidence and outcomes of diabetes mellitus in elderly people: Report from the Canadian Study of Heath and Aging. Can Med Assoc J 2000;162:769772.
  • 19
    Bourdel-Marchasson I, Dubroca B, Letenneur L et al. Incidence and predictors of drug-treated diabetes in elderly French subjects. The PAQUID epidemiological survey. Diabet Med 2000;17:675681.
  • 20
    Ferrara A, Barrett-Connor E, Shan J. Total, LDL, and HDL cholesterol decrease with age in older men and women: The Rancho Bernardo Study 1984–1994. Circulation 1997;96:3743.
  • 21
    Rosack J. FDA to require diabetes warning on antipsychotics. Psychiatric News 2003;38:1.
  • 22
    U.S. Food and Drug Administration. Warning about hyperglycemia and atypical antipsychotic drugs. FDA Safety News [on-line] June 2004. Available at Accessed March 11, 2010.
  • 23
    Komossa K, Rummel-Kluge C, Schmid F et al. Olanzapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev 2010;3:CD006654.
  • 24
    Komassa K, Rummel-Kluge C, Schmid F et al. Aripiprazole versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev 2009;4:CD006569.
  • 25
    Meyer JM, Davis VG, Goff DC et al. Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: Prospective data from phase 1. Schizophr Res 2008;101:273286.
  • 26
    Brown RR, Estoup MW. Comparison of the metabolic effects observed in patients treated with ziprasidone versus olanzapine. Int Clin Psychopharmacol 2005;20:105112.
  • 27
    Simon V, van Winkel R, De Hert M. Are weight gain and metabolic side effects of atypical antipsychotics dose dependent? A literature review. J Clin Psychiatry 2009;10:10411050.